Bristol-Myers Squibb to buy Mirati Therapeutics
Bristol-Myers Squibb is set to purchase cancer-drugmaker Mirati Therapeutics for around $5.8 billion. IGTV financial analyst @AngelineOng investigates why this is just the start of a pharma M&A wave.

Related articles
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.